This is a protocol for a Cochrane Review (intervention). The objectives are as follows:

To estimate the benefits and harms of:

Natalizumab compared with placebo or other disease-modifying therapies (DMT) as first‐choice treatment for people with any form of multiple sclerosis (MS);

Natalizumab compared with placebo or other DMT for all forms of MS, when switching from another DMT.